Screener
Biohaven BHVN Business Segments — R&D Share-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biohaven in its filing.
Tagged under the XBRL concept bhvn:ResearchAndDevelopmentExpenseShareBasedCompensationExpense.
The source filing: Biohaven’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001935979-26-000045
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other R&D program expense | 49 | 511 |
| Preclinical research programs R&D Expense | 8,549 | 25,535 |
| R&D personnel expense (excluding share-based compensation)(1) | 21,012 | 21,138 |
| R&D Share-based compensation expense | 18,475 | 35,233 |
| G&A personnel expense (excluding share-based compensation)(1) | 5,455 | 6,474 |
| G&A Share-based compensation expense | 9,811 | 17,829 |
| Other segment items (2) | 14,455 | 16,951 |
| Non-operating income | (168) | (493) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Biohaven's business segments — R&D share-based compensation expense?
- Biohaven (BHVN) reported business segments — R&D share-based compensation expense of $18.48M in Q1 2026.
- How has Biohaven's business segments — R&D share-based compensation expense changed year-over-year?
- Biohaven's business segments — R&D share-based compensation expense decreased by 47.6% year-over-year, from $35.23M to $18.48M.
- What is the long-term trend for Biohaven's business segments — R&D share-based compensation expense?
- Over 3 years (2022 to 2025), Biohaven's business segments — R&D share-based compensation expense has grown at a -14.5% compound annual growth rate (CAGR), from $116.38M to $72.79M.
- What does business segments — R&D share-based compensation expense mean?
- Represents the non-cash expense associated with equity-based awards granted to research and development staff. This metric highlights the cost of aligning employee incentives with long-term shareholder value within the R&D function. It is essential for understanding the total compensation structure and potential dilution effects.
Ask your AI about Biohaven's business segments — r&d share-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude